Synpromics is pleased to announce positive data presented on 18 October by a key partner, uniQure (NASDAQ:QURE), at the European Society of Gene and Cell Therapy conference in Lausanne, Switzerland. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.

The study, the first conducted in an advanced pre-clinical model using technology developed by Edinburgh-based Synpromics, demonstrates that the promoter is at least eight-times more potent than the current industry standard, providing uniQure with a powerful tool from which to drive the development of a variety of liver-directed gene therapies.

Commenting on the results, Dr Michael L Roberts, Founder & CSO of Synpromics, said: “This is fantastic data and shows the translatability of our company’s technology to advanced disease relevant models. This is the culmination of a productive partnership with uniQure in which we have worked closely to deliver a highly selective promoter, whose performance has exceeded initial expectations. This promoter enables uniQure to develop safer, targeted gene therapies for liver disease.”

This positive data supports the application of Synpromics’ technology in cell and gene therapies and further cements the company’s position as the leader in gene control.

For more information about Synpromics please visit